[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Intra-abdominal fat mass, or central adiposity, and cardiovascular risk are strongly correlated. Adipose tissue is an endocrine organ that secretes hormones and cytokines influencing appetite, energy metabolism, and atherosclerosis. Rimonabant is the first selective blocker of the cannabinoid-1 receptor in development for the treatment of obesity, diabetes mellitus typ 2, and cardiometabolic risk factors. This article provides an review of efficacy of rimonabant the first selective blocker of the cannabinoid-1 receptor.
Chatterjee
T
T
HerzZentrum Hirslanden Zentralschweiz, Hirslanden Klinik St. Anna, Luzern. tushar.chatterjee@hirslanden.ch
Ritz
A
A
Ince
H
H
Nienaber
Ch A
ChA
Rehders
T C
TC
D063387:Cannabinoid Receptor Antagonists; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant
D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant